• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    Lifecore Biomedical Enters into $150M New Financing Deal

    WuXi Biologics Receives 2023 ISPE Facility of the Year Award

    Thermo Fisher Expands Steriles Facility in Asia-Pacific Region

    GHO Capital, Partners Group Invest in Sterling Pharma Solutions
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    "3 Key Trends" with Cory Lewis

    WuXi Biologics Receives 2023 ISPE Facility of the Year Award

    Thermo Fisher Expands Steriles Facility in Asia-Pacific Region

    GHO Capital, Partners Group Invest in Sterling Pharma Solutions
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    TraceLink, PharmaLink Partner to Simplify DSCSA Compliance

    "3 Key Trends" with Rafael Costa

    Schreiner MediPharm Introduces Tailored Tamper-Proof Closure Seals

    FDA Watch: Is Your Supply Chain at Risk?
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    "3 Key Trends" with Cory Lewis

    Lifecore Biomedical Enters into $150M New Financing Deal

    WuXi Biologics Receives 2023 ISPE Facility of the Year Award

    Thermo Fisher Expands Steriles Facility in Asia-Pacific Region
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?

    FDA Watch: Is Your Supply Chain at Risk?

    FDA Watch: CDER to Launch Guidance Snapshot Pilot Program

    "3 Key Trends" with Paul Josephs
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    LOTTE BIOLOGICS

    Societal CDMO

    Syngene International Ltd.

    Federal Equipment Company

    U.S. Pharmacopeia (USP)
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    LOTTE BIOLOGICS

    Societal CDMO

    Syngene International Ltd.

    Federal Equipment Company

    U.S. Pharmacopeia (USP)
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    GDUFA and CMOs

    Will a new user fee affect CMOs and API suppliers?

    Gil Roth01.23.12

    Generics are big business, heading towards $90 billion in annual sales as mega-blockbusters lose patent protection and more markets push for containment of healthcare costs. In the U.S., which comprises more than 40% of the global market, the FDA seems ready to overhaul the generic application and inspection process. But how will it impact those suppliers that work with generic drugmakers?


    After more than a year of conversation and negotiation, the FDA has proposed a user fee for generic drugmakers. The Generic Drug User Fee Act (GDUFA) hasn’t been enacted by the U.S. Congress yet, but hearings are scheduled for February 2012 by the House Energy and Commerce Committee, and we could see passage of a five-year term in time for the 2013 fiscal year.


    At a speech to the Generic Pharmaceutical Association (GPhA) last year, FDA Commissioner Margaret Hamburg declared the need for a GDUFA, remarking, “We are at something of a tipping point . . . Looking ahead, it is clear that FDA will not be able to make ends meet with current resourcing, and more approvals will be delayed because of a lack of inspectional resources. That is why it is so important . . . to constructively address the Generic Drug User Fee. No one benefits from a pending-application queue of 2,000-plus products. Uncertainty and delays are costly to consumers, costly to industry — and hurtful to the public.”


    FDA reports that it receives between 800 and 900 generic drug-related applications each year, and it revised that pending-application estimate to something in excess of 2,500 ANDAs. Under the current proposal, the GDUFA would bring in $299 million annually from industry for five years. Application fees from drugmakers would comprise 30% of that sum ($90 million), with the rest coming from “facility fees” to inspect API suppliers and dosage form manufacturing sites. Fees from API suppliers would total $42 million and dosage form facility fees would be $168 million.


    But first, the FDA needs to clear out all those old applications, so the GDUFA’s initial year of funding (FY13) would include $50 million in backlog fees to speed up long-pending ANDAs. And, boy, are they long-standing. The average review time for an ANDA is around 30 months, compared to 10 months for innovative drugs.


    The agency projects that, by 2017, backlog would be eliminated and review times would be significantly reduced, with 90% of electronically-submitted ANDAs reviewed and acted upon within 10 months. (FDA also projects that it’ll get to 90% of all ANDAs that are outstanding on October 1, 2012 by the end of 2017, which raises the question of how stubborn those last 10% are going to be.)


    Still, why a facility fee in addition to the application fee? Kyle Sampson, a partner at Washington, DC law firm Hunton & Williams (and FDA Watch columnist for this magazine), commented, “The usual justification for user fee programs is that FDA needs additional resources so that it can approve drug applications more quickly. With regard to generic drug user fees, however, the Generic Pharmaceutical Association (GPhA) signaled early on in negotiations with FDA that the generic industry supports allocating a portion of generic drug user fees toward an additional purpose — enhancing drug quality and safety. Under GDUFA, FDA would not only have additional resources to review and approve ANDAs more speedily, the agency also would have additional resources to conduct more inspections — both in the U.S. and overseas.”


    In fact, the FDA has three key goals for the GDUFA, according to a draft statement:

     

    • Safety – “Ensure that industry participants, foreign or domestic, who participate in the U.S. generic drug system are held to consistent high quality standards and are inspected biennially, using a risk-based approach, with foreign and domestic parity.”
    • Access – “Expedite the availability of low cost, high quality generic drugs by bringing greater predictability to the review times for abbreviated new drug applications, amendments and supplements, increasing predictability and timeliness in the review process.”
    • Transparency – “Enhance FDA’s ability to protect Americans in the complex global supply environment by requiring the identification of facilities involved in the manufacture of generic drugs and associated active pharmaceutical ingredients, and improving FDA’s communications and feedback with industry in order to expedite product access.”

     

    If the GDUFA is enacted as proposed (and there’s no guarantee of that, given this Congress), what impact will $210 million in annual facility fees have on how CMOs and API suppliers who work with generic drugmakers?


    While some CMOs I spoke to believe that the fee wouldn’t apply to their sites, the FDA confirmed to me that the fee applies to any facility  involved in the manufacture of generics. According to the GDUFA, “Facilities identified, or intended to be identified, in at least one generic drug submission that is pending or approved to produce a finished dosage form of a human generic drug or an active pharmaceutical ingredient contained in a human generic drug shall be subject to fees. . .” That definition includes in-house generic facilities, but also has CMOs that work with generic companies square in its sights.


    I asked Clive Bennett, president and chief executive officer of Whippany, NJ-based Halo Pharmaceutical, what effect he thought the facility fee would have on CMOs working with generics. He said, “None . . . except that we will be forced to no longer make generics for generic firms unless the companies that we do generic work for allow us to pass the facility fee back to them. This will be a common reaction amongst CMOs.”


    He added, “What’s more, this approach is illogical. Facility fees for existing products will only tend to increase the price of current generics on the market. The purpose of the legislation (surely?) is to charge a fee for ANDAs so that the generic division gets better funding such that more new generics get approved. Those are totally different outcomes.”


    Mr. Bennett noted that the proposal smacked of ‘no taxation without representation,’ commenting, “To the best of my knowledge, the generic companies have been pushing for this — but also to the best of my knowledge CMOs have not been represented.”


    It put me in mind about what Billy Tauzin (apocryphally?) said when he was president of PhRMA and helped negotiate the industry’s contribution to President Obama’s healthcare act. Criticized for ‘working with the enemy,’ he noted, “If you’re not at the table, then you’re on the menu.”


    Regarding Mr. Bennett’s contention that the imposition of $299 million in new fees will raise the price of generics, the FDA has argued that, dispersed across the spectrum of the generic market in the U.S., the cost will come out to a mere dime per prescription, and could conceivably lead to cost savings, if more products are approved in a more timely manner.


    Still, the question remains: Are the GDUFA’s three goals — safety, access and transparency — at odds with each other? Can a single program target all three, or is it a case of “good, fast, cheap: pick two”?


    Dr. Robert Hardy, chief executive officer of Aesica Pharmaceuticals, a UK-based API manufacturer, pointed out a discrepancy in the GDUFA as currently proposed. Coming from the safety/inspection perspective, he remarked, “We welcome any initiatives to make medicines safer for patients and outlaw disreputable manufacturers. The big question is, should CMOs in regions that are already highly regulated, such as Europe, be made to pay for countries with poorer quality standards?”


    He added, “Ultimately, U.S. consumers and health insurers reap the benefits of cheap medicines and they push hard for competitive pricing, which drives demand from China and India. When prices come down, something has to give; in this case it’s the stringency of the auditing process. If the U.S. government wants to raise standards and continue to enjoy lower drug prices, it should cover the cost of a joined-up global auditing process where China’s SFDA and its international equivalents work to the same parameters, rather than duplicating effort by introducing additional inspections.”


    The GDUFA does stipulate that facility fees for non-U.S. API and dosage form suppliers will be between $15,000 and $30,000 more than for a U.S. facility, which can be read either as recognition of the added hurdles of overseas inspections or a method of penalizing generic drugmakers that use non-U.S. labor (or both). In addition, according to the GDUFA goals and preferences draft document, “FDA will undertake a study of foreign government regulator inspections (CGMP and bioequivalence), report findings publicly, and develop a program to utilize foreign inspection classifications when and where appropriate.”


    Dr. Hardy at Aesica commented, “The GDUFA as currently proposed will create a trade barrier for non-U.S. CMOs and make it even more challenging for European suppliers to compete for U.S. business.”


    Thomas M. Speace, president and chief executive officer of Neuland Laboratories Inc., an API manufacturer based in India, was more sanguine about the GDUFA. He remarked, “I think the generic industry, as well as the associations representing the member companies, are aligned on the need for these fees. This wasn’t the case earlier when the industry was dominated by founder/entrepreneurs at each company.”


    The fee schedule is still unclear for Drug Master Files (DMFs), facility inspections and annual facility registrations, the three areas that would impact Neuland. No one is exactly clear on how many facilities, both in-house and outsource, are involved in generic manufacturing, so there’s little guidance on how the fees will be distributed.


    Mr. Speace said that he heard rumors of a $50,000 fee for a DMF and that the cost for inspection around the same, presumably for an overseas operation like Neuland. He commented, “The fees will increase everyone’s cost of doing business, but the large generic companies, such as Teva, Mylan and Watson, will view this as a cost of doing business which will be recouped by earlier entry into the market.”


    This raises another concern about the GDUFA; laws that impose uniform fees on marketers of different sizes tend to — and maybe are intended to — price smaller competitors out of the market. As Mr. Speace said, for the major generic companies, these costs can be written off, but for smaller firms, they can mean the difference between profit and loss, which could lead to a smaller pool of generic drugmakers. Could it have the same effect on smaller API and dosage form suppliers, especially in non-U.S. markets, leading to the trade barrier Dr. Hardy warns of?

     

    Innovative drug companies have been paying user fees since the PDUFA was first enacted in 1992. It only makes sense, given the rising importance of generic drugs and the criticality of their safety, that they shoulder some of the regulatory burden. As Mr. Speace put it, “The ability to file DMFs, have your facility inspected by FDA free of charge and not pay any associated fees for ANDA review and approvals, which are required to gain access to the biggest pharmaceutical market in the world, has been the biggest bargain on the planet for domestic and foreign firms and that is about to change.” 


     

    Gil Roth has been the editor of Contract Pharma since its debut in 1999. He can be reached at gil@rodpub.com

    Related Searches
    • contract pharma
    • Manufacturing
    • Pharma
    • Dosage
    Suggested For You
    COVID Booster Vaccines: What’s Next for FDA COVID Booster Vaccines: What’s Next for FDA
    The Future of Clinical Trials The Future of Clinical Trials
    Let’s Get Genuine Let’s Get Genuine
    Maintaining Critical Drug Supply During COVID-19 Maintaining Critical Drug Supply During COVID-19
    Global Outsourcing Trends Global Outsourcing Trends
    Clinical Trials are Transforming Right Before Our Eyes Clinical Trials are Transforming Right Before Our Eyes
    Modularity in Injectables Manufacturing Modularity in Injectables Manufacturing
    Astellas, LabCentral Partner to Help Emerging Biotechs Accelerate Research Astellas, LabCentral Partner to Help Emerging Biotechs Accelerate Research
    Fortifying Logistics with Technology for Decentralized Trials Fortifying Logistics with Technology for Decentralized Trials
    A Look Into COVID Vaccines, Development and Outsourcing A Look Into COVID Vaccines, Development and Outsourcing
    The Real Cost of Bringing Manufacturing Home The Real Cost of Bringing Manufacturing Home
    Veklury Drives 2Q Growth for Gilead Veklury Drives 2Q Growth for Gilead
    AbbVie AbbVie's 2Q Revenue up 34%
    BMS 2Q Revenues up 16% BMS 2Q Revenues up 16%
    Action Trumps Fear Action Trumps Fear

    Related Online Exclusives

    • Biologics, Proteins, Vaccines
      COVID Booster Vaccines: What’s Next for FDA

      COVID Booster Vaccines: What’s Next for FDA

      FDA Atty comments on the ongoing vaccine rollout what we can expect for other COVID vaccines in development going forward.
      09.13.21

    • Clinical Trials
      The Future of Clinical Trials

      The Future of Clinical Trials

      Dr. Greg Licholai of ICON plc on key market trends, the future of clinical trials and the acquisition of PRA.
      Kristin Brooks, Managing Editor 09.09.21

    • Let’s Get Genuine

      Let’s Get Genuine

      LinkedIn sales pitches are going away in favor of being real.
      David G. Jensen, Contributing Editor 09.09.21


    • Logistics | Supply Chain
      Maintaining Critical Drug Supply During COVID-19

      Maintaining Critical Drug Supply During COVID-19

      Vincent Colicchio from Dr. Reddy’s talks about the challenges and solutions of maintaining supply during the pandemic.
      Tim Wright, Editor, Contract Pharma 09.09.21

    • Global Outsourcing Trends

      Global Outsourcing Trends

      Lonza’s Jan Vertommen talks about building global manufacturing and development networks to advance innovative, life-saving therapies.
      Tim Wright, Editor, Contract Pharma 09.09.21

    Loading, Please Wait..
    Trending
    • Aurigene Expands Biologics CDMO Capacity
    • Contract Pharma
    • Catalent Adds New Cryogenic Capabilities At Japanese Facility
    • Societal CDMO Partners With Atossa Therapeutics
    • Videobite: Contract Pharma Sits Down with Ryan Lake of Societal CDMO
    Breaking News
    • Catalent Adds New Cryogenic Capabilities at Japanese Facility
    • Lifecore Biomedical Enters into $150M New Financing Deal
    • WuXi Biologics Receives 2023 ISPE Facility of the Year Award
    • Thermo Fisher Expands Steriles Facility in Asia-Pacific Region
    • GHO Capital, Partners Group Invest in Sterling Pharma Solutions
    View Breaking News >
    CURRENT ISSUE

    May 2023

    • New Modalities Hog the Limelight
    • Cell and Gene Therapy is Coming of Age
    • Demand Surges for Cell and Gene Therapy Contract Manufacturing
    • Embracing a New Reality
    • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
    • Single-Use Technologies Enable Biologic Scaling
    • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    • FTEs in Drug Discovery
    • Digital Transformation in Pharma
    • What is a Manufacturing Ecosystem and Why are They Growing?
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Premium Label & Packaging Solutions Receives Safe Quality Food (SQF) Certification
    Inulinase Enzymes May Benefit Gut Symptoms of FODMAP Digestion
    Verdure Sciences’ Boswellia Ingredient Receives USP Verification
    Coatings World

    Latest Breaking News From Coatings World

    OQ Chemicals Launches Cost-Cutting Program and Organizational Realignment in Germany
    BASF Strengthens R&D with More Powerful Supercomputer
    Safic-Alcan Expands its Presence in Africa with the Launch of Safic-Alcan East Africa in Kenya
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Vascular Surgeon Imprisoned and Fined for Decade-Long Healthcare Fraud
    Remote Monitoring, Digital Health Help Advance Wound Care Treatment
    MLM Biologics Developing Wound Infection Prevention Device for Military
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Catalent Adds New Cryogenic Capabilities at Japanese Facility
    Lifecore Biomedical Enters into $150M New Financing Deal
    WuXi Biologics Receives 2023 ISPE Facility of the Year Award
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    How Robots & Artificial Intelligence are Transforming Unilever's Material Innovation Factory
    Top 10 Most Popular Hair Care Brands in the U.S.—Ranked by Searches
    Aloette Cosmetics Launches Daily Mineral Shield Sunscreen
    Happi

    Latest Breaking News From Happi

    Revieve Launches Beauty Technology Platform on Google Cloud Marketplace
    BBW’s Fabric Softener Launch, Ameon’s New Ambassador
    Mielle Organics Taps Angel Reese as New Ambassador
    Ink World

    Latest Breaking News From Ink World

    Weekly Recap: INX Digital, Mexar and hubergroup Top This Week’s Stories
    Richnerstutz AG Acquires an EFI VUTEk Q5r Superwide Roll-to-Roll Printer
    BASF Strengthens Its R&D with More Powerful Supercomputer
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Mactac acquires Label Supply, Beontag grows and more
    Sun Chemical releases Spring 2023 Regulatory Newsletter
    Tageos unveils new RAIN RFID inlays
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Weekly Recap: Corman, Tosama Develop Biodegradable Plastic Tampon Applicator, Trevira Changes Name
    Suominen Appoints SVP, Transformation Management Office
    Minnesota Signs PFAS Ban in Consumer Products
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    AlloSource Launches AlloMend Duo Acellular Dermal Matrix
    TendoNova Inks Partnership With AcCELLerated Biologics
    Stryker Achieves First Surgeries Using Q Guidance System with Cranial Guidance Software
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Weekly Recap: Smart Skis, Universal Display Top This Week’s Stories
    Wiliot Appoints Antony Yousefian as VP of Climate & Circularity
    HID Unveils Eco-friendly Bamboo Access Cards

    Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login